FORT MYERS, Fla. (AP) — FORT MYERS, Fla. (AP) — NeoGenomics Inc. (NEO) on Tuesday reported a loss of $14.3 million in its fourth quarter.
The Fort Myers, Florida-based company said it had a loss of 11 cents per share. Earnings, adjusted for amortization costs and stock option expense, came to 3 cents per share.
The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 1 cent per share.
The operator of cancer-focused testing laboratories posted revenue of $155.6 million in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $152.9 million.
For the year, the company reported a loss of $88 million, or 70 cents per share. Revenue was reported as $591.6 million.
NeoGenomics expects full-year revenue in the range of $650 million to $660 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NEO at https://www.zacks.com/ap/NEO